You are here

P&T News

May 26

“Immutable” changes are on the way, regardless of government policies
Causes include growing population of older adults
First biosimilar erythropoiesis-stimulating agent backed by an FDA panel
Finger of suspicion points to Ocrevus, but Tysabri may be the real culprit

May 25

Potentially harmful bacteria acquire antibiotic-resistance genes
Company plans FDA submission by mid-year
Proposed legislation trims $119 billion from federal deficit

May 24

STAT article lists eight ways proposed cuts might affect public health
Approval marks major step in precision medicine
Two-year study shows 2.8% improvement in disease-free survival versus placebo

May 23

California takes steps to reduce overly aggressive care
Centers postpone operations, delay chemotherapy
Wholesale acquisition cost is $39,000 per year

Pages